Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 7

CHEMBL3155 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:17:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3155
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 7 as ChEMBL target CHEMBL3155, mapped to UniProt P34969. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 7
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3155
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P34969
5-hydroxytryptamine receptor 7
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 7 matters

As of 2026-09-13

5-hydroxytryptamine receptor 7 is reviewed as 5-hydroxytryptamine receptor 7 (UniProt P34969); 5-hydroxytryptamine receptor 7 shows clinical signal disease relevance led by bipolar disorder. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 48 approved drugs, 4575 compounds, and 793 assays, with lead potency reaching pChEMBL 10.0.

Disease context
bipolar disorder

5-hydroxytryptamine receptor 7 shows clinical signal disease relevance led by bipolar disorder. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include JNJ-18038683.

Start review with bipolar disorder because it currently carries clinical signal support. Linked drugs include JNJ-18038683. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 48 approved drugs, 4575 compounds, and 793 assays for this target. The dominant activity type is KI. CHEMBL5789483 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5789483 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
48 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 7 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P34969, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why bipolar disorder is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4575
Total Compounds
793
Total Assays
48
Approved Drugs
IC50: 740.0, KI: 3668.0, EC50: 316.0, KD: 9.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5789483
 10.0 Ki —
No preferred name
CHEMBL3289972
 10.0 Ki —
No preferred name
CHEMBL39
 10.0 Ki Clinical
No preferred name
CHEMBL592752
 9.8 Ki Clinical
No preferred name
CHEMBL5179460
 9.8 Ki —

Approved Drugs

Structure Compound First Approval
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
 2015
BREXPIPRAZOLE
CHEMBL2105760
 2015
CARIPRAZINE
CHEMBL2028019
 2015
VORTIOXETINE
CHEMBL2104993
 2013
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
LURASIDONE
CHEMBL1237021
 2010
SILODOSIN
CHEMBL24778
 2008
PALIPERIDONE
CHEMBL1621
 2006
CINACALCET HYDROCHLORIDE
CHEMBL1200776
 2004
ARIPIPRAZOLE
CHEMBL1112
 2002
FROVATRIPTAN SUCCINATE
CHEMBL2138684
 2001
ZIPRASIDONE
CHEMBL708
 2001
KETOTIFEN FUMARATE
CHEMBL1633
 1999
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
 1999
QUETIAPINE
CHEMBL716
 1997
TAMSULOSIN
CHEMBL836
 1997
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
 1996
MIRTAZAPINE
CHEMBL654
 1996
OLANZAPINE
CHEMBL715
 1996
SALMETEROL
CHEMBL1263
 1994
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
 1994
CISAPRIDE
CHEMBL1729
 1993
RISPERIDONE
CHEMBL85
 1993
SUMATRIPTAN
CHEMBL128
 1992
CLOZAPINE
CHEMBL42
 1989
AMISULPRIDE
CHEMBL243712
 1986
BUSPIRONE
CHEMBL49
 1986
AMOXAPINE
CHEMBL1113
 1980
MOLINDONE
CHEMBL460
 1974
CLONIDINE HYDROCHLORIDE
CHEMBL1705
 1974
HALOPERIDOL
CHEMBL54
 1967
METHYSERGIDE
CHEMBL1065
 1962
THIORIDAZINE
CHEMBL479
 1962
CYPROHEPTADINE
CHEMBL516
 1961
FLUPHENAZINE
CHEMBL726
 1959
PERPHENAZINE
CHEMBL567
 1957
CHLORPROMAZINE
CHEMBL71
 1957
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
 1946
MIANSERIN
CHEMBL6437
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:17:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3155